dulaglutide (trulicity) Report issue

Biologics Peptide Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$23.2241

United States

$140.2700 - $205.7875
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

dulaglutide | ly2189265 | ly 2189265 | ly-2189265 | ly3002815 | trulicity

Organizations (45)

Research & Development (45)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (40)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (40)


 

Adiposity (Phase 4)

Blood Glucose (Phase 4)

Body Weight Changes (Phase 2)

Cardiovascular Diseases (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 2)

Chronic Pain (Phase 3)

Craving (Phase 2)

Cystic Fibrosis (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 ()

Diabetic Nephropathies (Phase 4)

Endocrine System Diseases (Phase 3)

Endothelial Cells (Phase 2)

Exocrine Pancreatic Insufficiency (Phase 2)

Fatty Liver (Phase 4)

Glucagon-Like Peptide 1 (Phase 2)

Glucose Intolerance (Phase 4)

Glucose Metabolism Disorders (Phase 3)

Healthy Volunteers (Phase 4)

Hepatic Insufficiency (Phase 1)

Hyperglycemia (Phase 4)

Hypoglycemic Agents (Phase 3)

Metabolic Diseases (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 4)

Obesity (Phase 4)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overweight (Phase 4)

Pharmacokinetics (Phase 4)

Polycystic Ovary Syndrome (Phase 4)

Polydipsia, Psychogenic (Phase 2)

Psychological Distress (Phase 4)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 3)

Sexual Health (Phase 2)

Sleep Apnea, Obstructive (Phase 3)

Smoking Cessation (Phase 2)

Thirst (Phase 2)

Water-Electrolyte Imbalance (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 106
  • # of Trial Organizations: 45

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue